Trial Profile
A randomized double blind study to investigate the effect of APC-2000 in patients with mild to moderate asthma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Apr 2015
Price :
$35
*
At a glance
- Drugs Salbutamol (Primary)
- Indications Asthma
- Focus Pharmacokinetics
- 21 Apr 2015 New trial record
- 16 Apr 2015 Primary endpoint (The equivalence of change from baseline in Forced Expiratory Volume (FEV1 AUC 0-6 hours) between the two HFA aerosols assessed at two different doses (100 and 200 mcg)) met, as per Adamis Pharmaceuticals media release.